Cerenome: Clinical Trials

5 trials sponsored by Cerenome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 1 active not recruiting, 1 completed. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Recruiting 3, Active not recruiting 1, Completed 1
Phase 22Active not recruiting 1, Recruiting 1

Follow Cerenome: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Rhenium-186 Nanoliposome - Ependymoma, High Grade Gliomas
Phase 1RecruitingCerenome562026-08-012026-09-11
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
186RNL - Leptomeningeal Metastasis
Phase 1 / Phase 2RecruitingCerenome242025-07-022026-11-05
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Retreatment Rhenium Liposome - Glioma
Phase 1RecruitingCerenome402024-12-122026-10-21
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
186RNL - Leptomeningeal Metastasis
Phase 1CompletedCerenome372021-12-062026-10-27
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Rhenium Liposome Treatment - Glioma
Phase 1 / Phase 2Active not recruitingCerenome552015-06-032026-11-09

Conditions studied

Brain Neoplasms (2)  ·  Glioblastoma (2)  ·  Glioma (2)  ·  Meningeal Carcinomatosis (2)  ·  Central Nervous System Neoplasms (1)  ·  Ependymoma (1)  ·  Meningeal Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Nervous System Diseases (1)  ·  Nervous System Neoplasms (1)  ·  Pathologic Processes (1)

Countries

United States (5)

Top investigators

Andrew J Brenner, PhD (2)  ·  Andrew Brenner, PhD (1)

Results publications

PMID 39032243

NIH funding

R01CA235800 (1)